Platinum resistant ovarian cancer, usually defined as progression occurring within 6 months
after completing platinum-based therapy, is a heterogeneous disease with poor prognosis …

Ovarian cancer has the highest mortality of all of the gynecological malignancies. There are
several distinct histotypes of this malignancy characterized by specific molecular events and …

Despite many improvements in ovarian cancer diagnosis and treatment, until now,
conventional chemotherapy and new biological drugs have not been shown to cure the …

Ovarian cancer has shown little improvement in survival among advanced-stage patients
over the past decade. Current treatment strategies have been largely unsuccessful in …

Ovarian cancer is the 5th most common and the deadliest gynecological cancer, with a 5-
year survival rate of less than 50 percent. Most deaths due to ovarian cancer are caused by …

Previously, based on a DNA microarray experiment, we identified a 96-gene prognostic
signature associated with the shorter survival of ovarian cancer patients. We hypothesized …

Most high‐grade ovarian carcinomas (HGOCs) are sensitive to carboplatin (CBP)‐based
chemotherapy but frequently recur within 24 months. Recurrent tumors remain CBP …

Among all gynecological malignancies, ovarian cancer (OC) accounts for the highest
mortality rate due to high therapeutic resistance, prolonged latency and a lack of effective …

Simple Summary The tumor-surrounding niche comprises not only cancer cells but also
stromal cells, signaling molecules, secreted factors and the extracellular matrix. This niche …

To generate robust patient-derived xenograft (PDX) models for epithelial ovarian cancer
(EOC), analyze the resemblance of PDX models to the original tumors, and explore factors …